[go: up one dir, main page]

WO1998036730A3 - Compositions de traitement de l'acne rosacee - Google Patents

Compositions de traitement de l'acne rosacee Download PDF

Info

Publication number
WO1998036730A3
WO1998036730A3 PCT/EP1998/000991 EP9800991W WO9836730A3 WO 1998036730 A3 WO1998036730 A3 WO 1998036730A3 EP 9800991 W EP9800991 W EP 9800991W WO 9836730 A3 WO9836730 A3 WO 9836730A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
acne rosacea
treating acne
rosacea
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1998/000991
Other languages
German (de)
English (en)
Other versions
WO1998036730A2 (fr
Inventor
Walter Diembeck
Udo Hoppe
Birgit Salzer
Gerhard Sauermann
Volker Steinkraus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19711565A external-priority patent/DE19711565A1/de
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Priority to JP53626998A priority Critical patent/JP2001512471A/ja
Priority to EP98913571A priority patent/EP0969790A2/fr
Publication of WO1998036730A2 publication Critical patent/WO1998036730A2/fr
Publication of WO1998036730A3 publication Critical patent/WO1998036730A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation, notamment l'utilisation topique, d'un ou plusieurs composés sélectionnés dans le groupe des inhibiteurs de la NO-synthase et de leurs dérivés pour la prophylaxie et/ou le traitement de l'acné rosacée et de la couperose.
PCT/EP1998/000991 1997-02-21 1998-02-20 Compositions de traitement de l'acne rosacee Ceased WO1998036730A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP53626998A JP2001512471A (ja) 1997-02-21 1998-02-20 しゅさの処置のための調製物
EP98913571A EP0969790A2 (fr) 1997-02-21 1998-02-20 Compositions de traitement de l'acne rosacee

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19706581 1997-02-21
DE19706581.3 1997-02-21
DE19711565.9 1997-03-20
DE19711565A DE19711565A1 (de) 1997-02-21 1997-03-20 Zubereitungen für die Behandlung von Rosacea

Publications (2)

Publication Number Publication Date
WO1998036730A2 WO1998036730A2 (fr) 1998-08-27
WO1998036730A3 true WO1998036730A3 (fr) 1998-10-22

Family

ID=26034114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/000991 Ceased WO1998036730A2 (fr) 1997-02-21 1998-02-20 Compositions de traitement de l'acne rosacee

Country Status (3)

Country Link
EP (1) EP0969790A2 (fr)
JP (1) JP2001512471A (fr)
WO (1) WO1998036730A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838563B2 (en) 2003-05-27 2010-11-23 Galderma Laboratories Inc. Compounds, formulations, and methods for ameliorating telangiectasias

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19918750A1 (de) * 1999-04-24 2000-10-26 Beiersdorf Ag Wirkstoffe, kosmetische und dermatologische Zubereitungen für die Verbesserung der Barrierefunktion
FR2794974B1 (fr) * 1999-06-16 2001-08-17 Exsymol Sa Composition cosmetique pour l'amincissement a base de l-arginine, d'un analogue de l-arginine ou d'un de leurs derives, applicable par voie topique
FR2808189B1 (fr) * 2000-04-28 2004-03-05 Oreal Lipochroman-6 comme inhibiteur de no-synthase et utilisations
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US20050020600A1 (en) 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
CN101822661A (zh) 2004-09-02 2010-09-08 克斯莫石油株式会社 健康功能改善剂
JP4814501B2 (ja) * 2004-09-02 2011-11-16 コスモ石油株式会社 抗酸化機能向上剤
JP4814567B2 (ja) * 2004-09-02 2011-11-16 コスモ石油株式会社 健康機能向上剤
JP4814568B2 (ja) * 2004-09-02 2011-11-16 コスモ石油株式会社 免疫機能向上剤
CA2666365C (fr) 2006-10-12 2016-08-09 Topaz Pharmaceuticals Llc Formulations topiques d'avermectine et procedes d'elimination et de prophylaxie de souches de poux susceptibles et resistantes au traitement
EP2116237A1 (fr) 2008-08-05 2009-11-11 Polichem SA Compositions pour traiter la rosacée comprenants du chitosane et un acide dicarboxylique
JP2011063541A (ja) * 2009-09-17 2011-03-31 Tokyo Institute Of Technology Ｌ−アルギニン結合因子の精製方法及びｌ−アルギニン様化合物のスクリーニング方法
EP2329849B1 (fr) 2009-11-18 2015-04-29 Galderma Research & Development Combinaison d'un agoniste du récepteur alpha-2 adrénergique et d'un agent anti-inflammatoire non stéroïdien pour traiter ou empêcher un trouble cutané inflammatoire
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
KR20150058551A (ko) 2010-03-26 2015-05-28 갈데르마 리써어치 앤드 디벨로프먼트 모세혈관 확장증의 안전하고 유효한 치료를 위한 개선된 방법 및 조성물
HUE033143T2 (en) 2010-03-26 2017-11-28 Galderma Res & Dev Preparations containing brimonidine for the treatment of erythema
EP2444068B2 (fr) 2010-10-21 2017-12-06 Galderma S.A. Composition de gel de brimonidine
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0631776A1 (fr) * 1993-07-02 1995-01-04 Roussel Uclaf Utilisation de dérivés de la bêta-naphtoquinone pour l'accélération de la prolifération des cellules endothéliales et de l'inhibition des no synthases
WO1995024884A1 (fr) * 1994-03-16 1995-09-21 Handelman, Joseph, H. Inhibition de la croissance pileuse
WO1996026711A1 (fr) * 1995-02-27 1996-09-06 L'oreal Inhibiteurs de no-synthase
WO1997015280A1 (fr) * 1995-10-26 1997-05-01 L'oreal Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
FR2744915A1 (fr) * 1996-02-16 1997-08-22 Oreal Composition cosmetique a base de cellules indifferenciees de ginkgo biloba

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0631776A1 (fr) * 1993-07-02 1995-01-04 Roussel Uclaf Utilisation de dérivés de la bêta-naphtoquinone pour l'accélération de la prolifération des cellules endothéliales et de l'inhibition des no synthases
WO1995024884A1 (fr) * 1994-03-16 1995-09-21 Handelman, Joseph, H. Inhibition de la croissance pileuse
WO1996026711A1 (fr) * 1995-02-27 1996-09-06 L'oreal Inhibiteurs de no-synthase
WO1997015280A1 (fr) * 1995-10-26 1997-05-01 L'oreal Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
FR2744915A1 (fr) * 1996-02-16 1997-08-22 Oreal Composition cosmetique a base de cellules indifferenciees de ginkgo biloba

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A.A.QURESHI ET AL.: "From Bedside to the Bench and Back", ARCH. DERMATOL., vol. 132, no. 8, August 1996 (1996-08-01), pages 889 - 903, XP002075669 *
G.SAUERMANN ET AL.: "Influence of NO-Synthase Antagonists in Rosacea Patients", J.INVEST DERMATOL., vol. 108, no. 4, April 1997 (1997-04-01), pages 657, XP002075670 *
S.M.BIRNBAUM ET AL.: "Preparation of the Optical Isomers of Arginine, Histidine and S-Benzylcysteine by Asymmetric Enzymatic Hydrolysis of their Acetyl Derivatives", ARCH.BIOCHEM., vol. 39, 1952, pages 108 - 118, XP002075668 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838563B2 (en) 2003-05-27 2010-11-23 Galderma Laboratories Inc. Compounds, formulations, and methods for ameliorating telangiectasias
US8426410B2 (en) 2003-05-27 2013-04-23 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US8993571B2 (en) 2003-05-27 2015-03-31 Galderma Laboratories, L.P. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders

Also Published As

Publication number Publication date
EP0969790A2 (fr) 2000-01-12
JP2001512471A (ja) 2001-08-21
WO1998036730A2 (fr) 1998-08-27

Similar Documents

Publication Publication Date Title
WO1998036730A3 (fr) Compositions de traitement de l'acne rosacee
CA2267186A1 (fr) Application d'inhibiteurs de la cyclogenase-2 au traitement et a la prevention du processus neoplasique
ZA981132B (en) Methods, compositions and articles for reducing or preventing the effects of inflammation.
WO2002072031A3 (fr) Composes de tetracycline substitue utilises en tant qu'antifongiques synergiques
WO1999004752A3 (fr) Procede pour le traitement de la pigmentation de la peau
WO2002047706A3 (fr) Inhibition sélective de la cox-2 au moyen d'extraits végétaux
WO1996021655A3 (fr) Inhibiteurs de la calpaine et/ou de la cathepsine b derives d'oxazolidine substituee
WO2000037107A3 (fr) Procede d'utilisation d'un inhibiteur de cyclooxygenase-2 et d'un inhibiteur de metalloproteinase matricielle en tant que therapie combinee dans le traitement de la neoplasie
WO2001015678A3 (fr) Utilisation topique d'agonistes des kappa opioides afin de traiter les douleurs oculaires
WO2001051043A3 (fr) Compositions et methodes de traitement de maladies neoplasiques au moyen de combinaisons de limonoides, de flavonoides et de tocotrienols
WO1999015167A3 (fr) Utilisation de limonoides et de flavonoides d'agrumes et de tocotrienols pour le traitement du cancer
WO2003053383A3 (fr) Utilisation cosmetique d’au moins une hydrophobine pour le traitement des matieres keratiniques
WO1994004541A3 (fr) Inhibiteurs de proteine kinase et composes apparentes combines avec du taxol
ZA973487B (en) Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment.
AU7629694A (en) Compositions for treating corns, calluses and warts
WO2001017543A3 (fr) Compositions et procedes permettant la prevention ou le traitement du cancer et de la perte osseuse associee au cancer
WO2000009101A3 (fr) Utilisation de composes oestrogenes en tant qu'agents antifongiques
AU2002232400A1 (en) Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis
WO1998022101A3 (fr) Procede d'utilisation d'inhibiteurs de cyclo-oxygenase-2 comme agents anti-angiogeniques
WO1998026770A3 (fr) Utilisation locale d'agonistes opioïdes kappa dans le traitement de la douleur oculaire
HK1039449A1 (zh) 治疗多发性硬化的方法
WO1998018440A3 (fr) Utilisation des inhibiteurs de l'activite de l'acide retinoique pour traiter les peaux sensibles
EP1171145A4 (fr) Utilisation de la catechine pour la prevention ou le traitement de la restenose coronarienne
MXPA00007394A (es) Compuestos, composiciones y metodos para tratar o evitar infeccion de neumovirus y enfermedades asociadas.
WO2000032765A3 (fr) Ribozymotherapie destinee au traitement et/ou a la prevention de la restenose

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998913571

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 536269

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09367748

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998913571

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998913571

Country of ref document: EP